Navigation Links
GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
Date:12/17/2007

TORONTO, Dec. 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing simple blood-based molecular diagnostic tests for the early detection of diseases and personalized health management, today announced that it has started collecting patient samples for clinical validation studies of its lead product under development, ColonSentry(TM).

In June 2006, GeneNews presented training set results at the American Society of Clinical Oncology (ASCO) Annual Meeting which demonstrated that the expression profile of five genes in patients with colorectal cancer could be differentiated from controls. Blood RNA samples from an Asian population were profiled to identify differentially expressed genes. This analysis yielded a combination of five genes that achieved sensitivity of 90% and specificity of 79% in the training set.

Since June 2006, GeneNews has collected more than 10,000 patient blood samples through a network of clinical collaborations spanning more than 20 centers in the US and Canada. Included in the 10,000 samples are more than 500 blood samples from patients confirmed by pathology to have colorectal cancer and an additional 500 blood samples from patients with pre-cancerous polyps. These samples are being used by GeneNews to refine and optimize its ColonSentry biomarker panel.

GeneNews is now initiating patient sample accrual under GCP ("Guidelines for Good Clinical Practice") to create a bank of North American patient samples that would be eligible for inclusion in clinical validation studies of ColonSentry. These studies are expected to commence in 2008 as the Company advances its development efforts. The Company expects to initially offer ColonSentry as a reference laboratory-based test while it pursues regulatory approval for an IVD ("in-vitro diagnostic") version of the test.

About Colon Cancer and Screening

In the US, colon cancer is the second leading cause of cancer deaths for men and the third leading cause of cancer deaths for women. Colon cancer has a very poor prognosis if it is diagnosed after the cancer has spread outside the colon; however, if it is detected early it is usually curable. Current screening tests are generally invasive, expensive, inconvenient or not readily available. As a result, the vast majority of patients in the developed world are not adequately screened. It is estimated that there are approximately 80 million people in the US over the age of 50 who require regular screening and that only approximately 35% of this group complies with current screening guidelines. Outside the US, screening compliance is much lower.

About GeneNews

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry, is a convenient and patient-friendly blood-based biomarker test that can detect colon cancer. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
5. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
6. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
9. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... with its clients in mind, the fresh look and added functionality give the ... “Recent years have seen a dynamic shift in agriculture – from precision farming ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... the pre-launch success of their revolutionary, veterinarian-designed product for indoor cats. The NoBowl ... and play with their food the way nature intended. NoBowls make cats happy ...
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... New York , April 29, 2016 /PRNewswire/ ... report published by Transparency Market Research "Separation Systems ... Size, Share, Growth, Trends, and Forecast 2015 - ... was valued at US$ 10,665.5 Mn in 2014 ... of 6.8% from 2015 to 2023 to reach ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):